Rule 3.19A.2

# Appendix 3Y

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Actinogen Medical Limited
ABN	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Malcolm McComas
Date of last notice	18 November 2021

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct
	2. Indirect
	3. Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.  Date of change	<ol> <li>Bunyula Super Pty Ltd <bunyula a="" c="" fund="" super=""> -         director related entity and contingent beneficial interest</bunyula></li> <li>McComas Capital Pty Ltd <mccomas a="" c="" family=""> -         controller of trustee &amp; a beneficiary of the trust</mccomas></li> <li>December 2021</li> </ol>
No. of securities held prior to change	<ol> <li>3,000,000 unlisted options exercisable at \$0.10 each on or before 4 April 2024.</li> <li>600,000 fully paid ordinary shares.</li> <li>1,000,000 fully paid ordinary shares issued pursuant to Employee Share Plan.</li> </ol>
Class	Fully paid ordinary shares
Number acquired	2. 222,223
Number disposed	-
Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation	\$30,000

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held after change	<ol> <li>3,000,000 unlisted options exercisable at \$0.10 each on or before 4 April 2024.</li> <li>822,223 fully paid ordinary shares.</li> <li>1,000,000 fully paid ordinary shares issued pursuant to Employee Share Plan.</li> </ol>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares pursuant to share purchase plan

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

## Part 3 – \*Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

<sup>+</sup> See chapter 19 for defined terms.